Cited by 191SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesVaccine Coverage and Hesitancy

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273

Open access

Teo, Shyh Poh·2022·Journal of Pharmacy Practice

DOI 10.1177/08971900211009650

Open this paper in CoChat — free account Open PDF

Abstract

The United States Food and Drug Administration recently issued emergency use authorization for 2 mRNA vaccines for preventing COVID-19 disease caused by SARS-CoV-2 virus infections. BNT162b2 from Pfizer-BioNTech and mRNA-1273 by Moderna are planned for use in mass-immunization programs to curb the pandemic. A brief overview of COVID-19 mRNA vaccines is provided, describing the SARS-CoV-2 RNA, how mRNA vaccines work and the advantages of mRNA over other vaccine platforms. The Pfizer-BioNTech collaboration journey to short-list mRNA vaccine candidates and finally selecting BNT162b2 based on safety data is outlined, followed by the Phase 3 study of BNT162b2 demonstrating 95% efficacy in preventing COVID-19 infections. Studies regarding mRNA-1273 (Moderna) are described, including extended immunogenicity data up to 119 days. The Phase 3 COVE study of mRNA-1273 eventually showed vaccine efficacy of 94.5%. Recommendations for future mRNA vaccine development are provided, including ongoing safety surveillance, evaluation in under-represented groups in previous studies and improving mRNA vaccine thermostability. Finally, further logistical considerations are required for manufacturing, storing, distribution and implementing mass vaccination programs to curb the pandemic.

Integrity signals

Registry

Crossref · 10.1177/08971900211009650

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“Although the duration of protection from a singledose remains uncertain, a second dose does not appear to confer much additional benefit for the vaccine recipients.(29) In the Moderna trial, 81 (0.”
Background
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · cited 1×
“During the phase 1, dose-escalation trial, 45 healthy adults aged 18 to 55 years were administered 2 doses of 25 mg, 100 mg or 250 mg of mRNA-1273 28 days apart.(18) In this study, there was a dose-dependent antibody response; with increasing titers and serum-neutralizing activity after the second vaccination at the u…”
Method
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066

Flagged first, then by citations

Show all 26 references

Research works printed but not linked: 7

Corman VM, 2020, Eur Secur, 25, 2000045
Wang F, 2020, Med Sci Monit, 26, e924700
Vogel AB, 2020, bioRxiv, 12, 421008
10.1038/s41586-020-2639-4 · DOI · Paper page
Sahin U, 2020, medRxiv, 12, 20245175
10.1056/NEJMoa2027906 · DOI · Paper page
Skowronski DM, 2021, N Eng J Med, 384, 10

Sorted by citations

Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications
Jeong, M., Lee, Y., Park, J., Jung, H., & Lee, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114990 · Cited by 232
Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer–BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines
Bansal, S., Perincheri, S., Fleming, T. P., Poulson, C., Tiffany, B. R., Bremner, R. M., & Mohanakumar, T. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100637 · Cited by 150
Two centuries of vaccination: historical and conceptual approach and future perspectives
Montero, D. A., Vidal, R. M., Velasco, J., Carreño, L. J., Torres, J. P., O., M. A. B., Tovar-Rosero, Y.-Y., Oñate, A. A., & O’Ryan, M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1326154 · Cited by 171
Current Developments and Challenges of mRNA Vaccines
Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 111
Correlating the Structure and Gene Silencing Activity of Oligonucleotide-Loaded Lipid Nanoparticles Using Small-Angle X-ray Scattering
Hammel, M., Fan, Y., Sarode, A., Byrnes, A. E., Zang, N., Kou, P., Nagapudi, K., Leung, D., Hoogenraad, C. C., Chen, T., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c01186 · Cited by 107
Lipid-Based Nanoformulations for Drug Delivery: An Ongoing Perspective
Rehman, M., Tahir, N., Sohail, M. F., Qadri, M. U., Duarte, S. O. D., Brandão, P., Esteves, T., Javed, I., & Fonte, P. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111376 · Cited by 112
mRNA vaccine sequence and structure design and optimization: Advances and challenges
Jin, L., Zhou, Y., Zhang, S., & Chen, S. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108015 · Cited by 89
Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing
Sarode, A., Fan, Y., Byrnes, A. E., Hammel, M., Hura, G. L., Fu, Y., Kou, P., Hu, C., Hinz, F. I., Roberts, J., et al. (2022) · Nanoscale Advances · doi:10.1039/d1na00712b · Cited by 78
Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections
Asr, M. H., Dayani, F., Segherloo, F. S., Kamedi, A., Neill, A. O., MacLoughlin, R. J., & Doroudian, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041127 · Cited by 73
The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology
Ye, Z., Harmon, J., Ni, W., Li, Y., Wich, D., & Xu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c12584 · Cited by 72
Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines
Gupta, S., & Pellett, S. (2023) · Toxins · doi:10.3390/toxins15090563 · Cited by 81
Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa
Tang, J., Cai, L., Xu, C., Sun, S., Liu, Y., Rosenecker, J., & Guan, S. (2022) · Nanomaterials · doi:10.3390/nano12020226 · Cited by 54
Nano-formulations in disease therapy: designs, advances, challenges, and future directions
Shi, Y., Li, X., Li, Z., Sun, J., Gao, T., Wei, G., & Guo, Q. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03442-7 · Cited by 58
Design Strategies for and Stability of mRNA–Lipid Nanoparticle COVID-19 Vaccines
Liu, T., Tian, Y., Zheng, A., & Cui, C. (2022) · Polymers · doi:10.3390/polym14194195 · Cited by 54
mRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 54
Characterization of mRNA therapeutics
Guimaraes, G. J., Kim, J., & Bartlett, M. G. (2023) · Mass Spectrometry Reviews · doi:10.1002/mas.21856 · Cited by 50
Pharmacovigilance and Its Importance for Primary Health Care Professionals
Hamid, A. A. A., Rahim, R., & Teo, S. P. (2022) · Korean Journal of Family Medicine · doi:10.4082/kjfm.21.0193 · Cited by 46
Self-citation
Cardiovascular consequences of viral infections: from COVID to other viral diseases
Schultheiß, H., Baumeier, C., Pietsch, H., Bock, C. –., Poller, W. C., & Escher, F. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab315 · Cited by 48
On the mechanism of tissue-selective gene delivery by lipid nanoparticles
Kimura, S., & Harashima, H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.052 · Cited by 46
Research progress on the quality control of mRNA vaccines
Hu, C., Bai, Y., Liu, J., Wang, Y., He, Q., Zhang, X., Cheng, F., Xu, M., Mao, Q., & Liang, Z. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2354251 · Cited by 45
Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines
Yang, M. J., Zhang, Z., Jin, P., Jiang, K., Xu, Y., Pan, F., Tian, K., Yuan, Z., Liu, X., Fu, J., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123695 · Cited by 43
Prophylactic and therapeutic vaccine development: advancements and challenges
Weerarathna, I. N., Doelakeh, E. S., Kiwanuka, L., Kumar, P., & Arora, S. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00222-x · Cited by 47
Nanomaterial-based delivery of vaccine through nasal route: Opportunities, challenges, advantages, and limitations
Kumar, M., Dogra, R., & Mandal, U. K. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103533 · Cited by 37
Artificial intelligence-driven circRNA vaccine development: multimodal collaborative optimization and a new paradigm for biomedical applications
Zhao, Y., & Wang, H. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf263 · Cited by 40
Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection
Byrnes, A. E., Dominguez, S. L., Yen, C.-W., Laufer, B. I., Foreman, O., Reichelt, M., Lin, H., Sagolla, M., Hötzel, K., Ngu, H., et al. (2023) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2023.05.005 · Cited by 38
Zwitterionic materials for nucleic acid delivery and therapeutic applications
He, S., & Liu, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.017 · Cited by 33
Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan
Izumo, T., Kuse, N., Awano, N., Tone, M., Sakamoto, K., Takada, K., Muto, Y., Fujimoto, K., Saiki, A., Ito, Y., et al. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2021.06.003 · Cited by 31
Delivery of nucleic acids using nanomaterials
Qin, Y., Ou, L., Zha, L., Zeng, Y., & Li, L. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00160-0 · Cited by 35
Nanoparticles and Antiviral Vaccines
Liu, S., Hu, M., Liu, X., Liu, X., Chen, T., Zhu, Y., Liang, T., Xiao, S., Li, P., & Ma, X. (2023) · Vaccines · doi:10.3390/vaccines12010030 · Cited by 35
RNA Therapeutics: Delivery Problems and Solutions—A Review
Pozdniakova, N. V., Generalov, E. A., Shevelev, A. B., & Tarasova, O. A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101305 · Cited by 37
mRNA vaccines: A novel weapon to control infectious diseases
Tian, Y., Deng, Z., & Yang, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1008684 · Cited by 29
Low-frequency ultrasound-mediated blood-brain barrier opening enables non-invasive lipid nanoparticle RNA delivery to glioblastoma
Elbaz, M., Ad-El, N., Chulanova, Y., Brier, D., Goldsmith, M., Bismuth, M., Brosque, A., Sher, D., Gutkin, A., Bar-On, D., et al. (2025) · doi:10.1101/2025.01.23.634427 · Cited by 28
Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates
Wu, Y., Zhang, H., Meng, L., Li, F., & Yu, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.906457 · Cited by 29
The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines
Sun, Z., Wu, T., Xie, H., Li, Y., Zhang, J., Su, X., & Qi, H. (2022) · Vaccines · doi:10.3390/vaccines10071103 · Cited by 29
Cardiac side effects of RNA‐based SARS‐CoV‐2 vaccines: Hidden cardiotoxic effects of mRNA‐1273 and BNT162b2 on ventricular myocyte function and structure
Schreckenberg, R., Woitasky, N., Itani, N., Czech, L., Ferdinandy, P., & Schulz, R. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16262 · Cited by 30
Analyzing the Systems Biology Effects of COVID-19 mRNA Vaccines to Assess Their Safety and Putative Side Effects
Hajjo, R., Sabbah, D. A., & Tropsha, A. (2022) · Pathogens · doi:10.3390/pathogens11070743 · Cited by 28
Development and application of ribonucleic acid therapy strategies against COVID-19
Lin, N., Liu, M., Gou, Y., Yang, Y., He, B., & Huang, J. H. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72706 · Cited by 26
Hurdles to healing: Overcoming cellular barriers for viral and nonviral gene therapy
Honrath, S., Burger, M., & Leroux, J. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125470 · Cited by 28
Review: N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?
Rubio‐Casillas, A., Cowley, D., Raszek, M., Uversky, V. N., & Redwan, E. M. M. M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131427 · Cited by 27
Advances in the study of LNPs for mRNA delivery and clinical applications
Wang, B., Shen, B., Xiang, W., & Shen, H. (2024) · Virus Genes · doi:10.1007/s11262-024-02102-6 · Cited by 22
Non‐Viral Gene Delivery Systems: Current Advances and Therapeutic Applications
Wang, F., Liang, L., Wang, C., Zhang, C., Ye, Y., Dou, L., Shi, L., Zhou, D., & Sun, X. (2025) · Chemistry - An Asian Journal · doi:10.1002/asia.202500684 · Cited by 22
Effect of Antigen Structure in Subunit Vaccine Nanoparticles on Humoral Immune Responses
Park, J., & Champion, J. A. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c01516 · Cited by 21
Identifying a causal link between prolactin signaling pathways and COVID-19 vaccine-induced menstrual changes
Hajjo, R., Momani, E., Sabbah, D. A., Baker, N., & Tropsha, A. (2023) · npj Vaccines · doi:10.1038/s41541-023-00719-6 · Cited by 20
Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review
Napuri, N., Curcio, D., Swerdlow, D. L., & Srivastava, A. K. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00648-2 · Cited by 18
Reactive oxygen species-responsive nanoplatforms for nucleic acid-based gene therapy of cancer and inflammatory diseases
Zhu, D., Chen, W., Lin, W., Li, Y., & Liu, X. (2021) · Biomedical Materials · doi:10.1088/1748-605x/ac0a8f · Cited by 17
Silver and Silver Nanoparticles for the Potential Treatment of COVID-19: A Review
Arjun, P. N. J., Sankar, B., Shankar, K. V., Kulkarni, N. V., Sivasankaran, S., & Shankar, B. (2022) · Coatings · doi:10.3390/coatings12111679 · Cited by 17
Avian influenza mRNA vaccine encoding hemagglutinin provides complete protection against divergent H5N1 viruses in specific-pathogen-free chickens
Wang, Z., Tian, C., Zhu, J., Wang, S., Ao, X., He, Y., Chen, H., Liao, X., Kong, D., Zhou, Y.-F., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03156-w · Cited by 18
Importance of Process Parameters Influencing the Mean Diameters of siRNA-Containing Lipid Nanoparticles (LNPs) on the in Vitro Activity of Prepared LNPs
Nakamura, K., Aihara, K., & Ishida, T. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-01016 · Cited by 18
RNA vaccines: The dawn of a new age for tuberculosis?
Li, J., Liu, D., Li, X., Wei, J., Du, W., Zhao, A., & Xu, M. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2469333 · Cited by 19
A brief review of mRNA therapeutics and delivery for bone tissue engineering
Rajendran, A. K., Amirthalingam, S., & Hwang, N. S.-Y. (2022) · RSC Advances · doi:10.1039/d2ra00713d · Cited by 16
Application of Saccharide Cryoprotectants in the Freezing or Lyophilization Process of Lipid Nanoparticles Encapsulating Gene Drugs for Regenerative Medicine
Li, W., Wang, T., Chen, J., Guo, M., Ling, L., & Higuchi, A. (2024) · Regenerative medicine and dentistry. · doi:10.53941/rmd.2024.100003 · Cited by 17
A mathematical model simulating the adaptive immune response in various vaccines and vaccination strategies
Xu, Z., Song, J. H., Zhang, H., Wei, Z., Wei, D., Guangyu, Y., Jacques Demongeot, A., & Zeng, Q. (2024) · Scientific Reports · doi:10.1038/s41598-024-74221-x · Cited by 15
The oral vaccine based on self-replicating RNA lipid nanoparticles can simultaneously neutralize both SARS-CoV-2 variants alpha and delta
Mohammadi, G., Koranni, Z. S., & Jebali, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108231 · Cited by 15
Comparison of capillary electrophoresis-based methods for the analytical characterization of purity and stability of in vitro transcribed mRNA
Mantri, P., Juneja, B., Henderson, S., Koufos, E., Moon, Y., Dayeh, D. M., Grandi, D. D., Fu, Y., Muthusamy, K., Ihnat, P. M., et al. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116352 · Cited by 16
Quantitative proteomics and biological activity of extracellular vesicles engineered to express SARS‐CoV‐2 spike protein
Choi, D., Khan, N., Montermini, L., Tawil, N., Meehan, B., Kim, D., Roth, F. P., Divangahi, M., & Rak, J. W. (2022) · Journal of Extracellular Biology · doi:10.1002/jex2.58 · Cited by 15
Agent-based model of the impact of higher influenza vaccine efficacy on seasonal influenza burden
Krauland, M. G., Zimmerman, R. K., Williams, K. V., Raviotta, J. M., Harrison, L. H., Williams, J. V., & Roberts, M. S. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100249 · Cited by 12
The optimization strategies of LNP-mRNA formulations: Development and challenges for further application
Wang, S., Guo, B., Wang, H., & Yang, F. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105547 · Cited by 14
Strategies for Organ‐Targeted mRNA Delivery by Lipid Nanoparticles
Liao, H., Liao, J. P., Zeng, L., Cao, X., Fan, H., & Chen, J. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.2004 · Cited by 13
Advancements in long non-coding RNA-based therapies for cancer: targeting, delivery, and clinical implications
Ammad, M., Javed, Z., Sadia, H., Ahmed, R., Akbar, A. U., Nadeem, T., Călina, D. C., & Sharifi‐Rad, J. (2024) · Medical Oncology · doi:10.1007/s12032-024-02534-y · Cited by 14
Breaking barriers: Smart vaccine platforms for cancer immunomodulation
Gomari, M. M., Ghantabpour, T., Pourgholam, N., Rostami, N., Hatfield, S. M., Namazifar, F., Abkhiz, S., Eslami, S. S., Ramezanpour, M., Darestanifarahani, M., et al. (2025) · 癌症：英文版 · doi:10.1002/cac2.70002 · Cited by 17
Microneedle‐Enabled Breakthroughs in Nucleic Acid Therapeutics
Wu, P., Zhang, T., Zhao, D., Xie, Y., Huang, D., Li, Z., & Huang, Y. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501015 · Cited by 15
Potential roles of mesenchymal stem cells and their exosomes in the treatment of COVID-19
Cheng, X., Jiang, M., Long, L., & Meng, J. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/4999 · Cited by 13
Application of Nanoparticles in Tumour Targeted Drug Delivery and Vaccine
Tu, Y., Yao, Z., Yang, W., Tao, S., Li, B., Wang, Y., Su, Z., & Li, S. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2022.948705 · Cited by 13
COVID-19 vaccination and liver disease
Ozaka, S., Kobayashi, T., Mizukami, K., & Murakami, K. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i48.6791 · Cited by 13
Recent research advances in the development of Dabie Banda virus vaccines
Yu, C., Lin, Y., Dai, Y., Wu, B., Qi, Z., & Qian, X. (2024) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0012411 · Cited by 12
Formulation, Device, and Clinical Factors Influencing the Targeted Delivery of COVID-19 Vaccines to the Lungs
Mossadeq, S., Shah, R., Shah, V., & Bagul, M. (2022) · AAPS PharmSciTech · doi:10.1208/s12249-022-02455-x · Cited by 13
Practical Considerations for Next-Generation Adjuvant Development and Translation
Lykins, W. R., & Fox, C. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071850 · Cited by 12
Current Development of Therapeutic Vaccines in Lung Cancer
Banda, J. S. F., Gangane, S., Raza, F., & Massarelli, E. (2025) · Vaccines · doi:10.3390/vaccines13020185 · Cited by 11
In vivo demonstration of enhanced mRNA delivery by cyclic disulfide-containing lipid nanoparticles for facilitating endosomal escape
Kimura, S., Okada, K., Matsubara, N., Lyu, F., Tsutsumi, S., Kimura, Y., Hashiya, F., Inagaki, M., Abe, N., & Abe, H. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00084j · Cited by 15
A self-amplifying mRNA vaccine expressing PRV gD induces robust immunity against virulent mutants
Ling, T., Zhang, X., Huan-huan, L., Ya-Ting, Z., Ya-mei, L., RongLi, G., DAMIANI, A. M., Sai-Sai, C., Chuan-jian, Z., Rui, D., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01251-5 · Cited by 13
Pharmacometric modeling of lipid nanoparticle-encapsulated mRNA therapeutics and vaccines: A systematic review
Zhang, M., Van, L. M., & Amiji, M. M. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102686 · Cited by 11
Controlling Circular RNA Encapsulation within Extracellular Vesicles for Gene Editing and Protein Replacement
Fang, L., Gu, W., Li, R., Chen, C., Cai, S., Luozhong, S., Chen, M., Hsu, A., Tsai, Y.-C., Londhe, K., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c07530 · Cited by 11
Clinical Characteristics of Patients with Myocarditis following COVID-19 mRNA Vaccination: A Systematic Review and Meta-Analysis
Matar, R., Mansour, R., Nakanishi, H., Smayra, K., Haddad, J. E., Vankayalapati, D. K., Daniel, R. S., Tosovic, D., Than, C. A., & Yamani, M. H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154521 · Cited by 11
A Brief Review on Medicinal Plants-At-Arms against COVID-19
Srivastava, S., He, F., Huang, Y., Niu, M., Adholeya, A., & Peng, W. K. (2023) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2023/7598307 · Cited by 10
Quantitative measurement of IgG to SARS‐CoV‐2 antigens using monoclonal antibody‐based enzyme‐linked immunosorbent assays
Sander, I., Kespohl, S., Zahradnik, E., Göcke, P., Hosbach, I., Herrmann, B. L., Brüning, T., & Raulf, M. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1369 · Cited by 9
Identification of genes related to immune enhancement caused by heterologous ChAdOx1–BNT162b2 vaccines in lymphocytes at single-cell resolution with machine learning methods
Li, J., Huang, F., Ma, Q., Guo, W., Feng, K., Huang, T., & Cai, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1131051 · Cited by 10
Evaluation of the immunoprotective effects of porcine deltacoronavirus subunit vaccines
Yu, R., Zhang, L., Zhou, P., Zhang, Z., Liu, X., Wang, Y., Guo, H., Li, P., & Liu, X. (2023) · Virology · doi:10.1016/j.virol.2023.109955 · Cited by 9
Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study
Chen, C., Chen, C., Cao, L., Fang, J., & Xiao, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112022 · Cited by 10
From Sequence to System: Enhancing IVT mRNA Vaccine Effectiveness through Cutting-Edge Technologies
Xu, L., Li, C., Liao, R., Xiao, Q., Wang, X., Zhao, Z., Zhang, W., Ding, X., Cao, Y., Cai, L., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00863 · Cited by 9
Nail psoriasis: a rare mRNA COVID ‐19 vaccine reaction
Lamberti, A., Lora, V., Graceffa, D., Bonifati, C., & Cota, C. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18255 · Cited by 9
Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations
Phan, T. X., Fan, D., & Melstrom, L. G. (2024) · Current Oncology · doi:10.3390/curroncol31090361 · Cited by 9
Cell-specific mRNA delivery via nanobody-functionalized lipid nanoparticles
Chen, L., der Weken, H. V., Zwaenepoel, O., Okkelman, I. A., Aelvoet, J., Denberghe, E. V., Gettemans, J., Dmitriev, R. I., Geest, B. G. D., Cox, E., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114365 · Cited by 10
M28 family peptidase derived from Peribacillus frigoritolerans initiates trained immunity to prevent MRSA via the complosome-phosphatidylcholine axis
Zhou, C., Liu, Z., Peng, Z.-R., Luo, X.-Y., Zhang, X., Zhang, J. G., Zhang, L., Chen, W., & Yang, Y. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2484386 · Cited by 7
Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans
Tscherne, A., Kalodimou, G., Kupke, A., Rohde, C., Freudenstein, A., Jany, S., Kumar, S., Sutter, G., Krähling, V., Becker, S., et al. (2024) · Vaccines · doi:10.3390/vaccines12121316 · Cited by 7
Shedding Lights on the Extracellular Vesicles as Functional Mediator and Therapeutic Decoy for COVID-19
Thakur, A. (2023) · Life · doi:10.3390/life13030840 · Cited by 7
A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses
Oreshkova, N., Myeni, S. K., Mishra, N., Albulescu, I. C., Dalebout, T. J., Snijder, E. J., Bredenbeek, P. J., Dallmeier, K., & Kikkert, M. (2021) · Vaccines · doi:10.3390/vaccines9121492 · Cited by 7
Real world pharmacovigilance study of antineoplastic drug related vitiligo risks
Yang, Y., Xie, H., Li, D., Jia, Y., Cui, B., Zou, J., & Xiao, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-06314-0 · Cited by 7
Engineering Delivery Technologies for Optimizing mRNA Vaccines
Gu, T., Yan, X., & Liu, S. (2025) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00032 · Cited by 7
Repeated COVID-19 Vaccination as a Poor Prognostic Factor in Pancreatic Cancer: A Retrospective, Single-Center Cohort Study
Abue, M., Mochizuki, M., Shibuya‐Takahashi, R., Ota, K., Wakui, Y., Iwai, W., Kusaka, J., Saito, M., Suzuki, S., Sato, I., et al. (2025) · Cancers · doi:10.3390/cancers17122006 · Cited by 8
Functional profiling of Covid 19 vaccine candidate by flow virometry
Prout, A., Rustandi, R. R., Tubbs, C. M., Winters, M. A., McKenna, P. M., & Vlasak, J. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.006 · Cited by 7
Adaptive immune response to BNT162b2 mRNA vaccine in immunocompromised adolescent patients
Bader, G., Itan, M., Edry‐Botzer, L., Cohen, H., Haskin, O., Mozer‐Glassberg, Y., Harel, L., Munitz, A., Marcus, N., & Gerlic, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1131965 · Cited by 5
Oral non-viral gene delivery platforms for therapeutic applications
Ghaemi, A., Azghandi, M. V., Abnous, K., Taghdisi, S. M., Ramezani, M., & Alibolandi, M. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123198 · Cited by 6
mRNA-based vaccines – global approach, challenges, and could be a promising wayout for future pandemics
Makhijani, S., Elossaily, G. M., Rojekar, S. V., & Ingle, R. G. (2024) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2024.2361656 · Cited by 7
Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine
Goda, K., Kenzaka, T., Yahata, S., Okayama, M., & Nishisaki, H. (2022) · Vaccines · doi:10.3390/vaccines10081232 · Cited by 6
Challenges and Opportunities Used in RNA-Based Therapeutics
Chauhan, P., Tiwari, I., & Sharma, N. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-3456-9_10 · Cited by 5
The stability landscape of mRNA vaccines: challenges and mitigation strategies
Zhong, L., Tao, L., Zhai, Z., Liao, L., Shi, C., Yao, S., & Liu, X. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128515 · Cited by 6
Optimization of a lipid nanoparticle–based protocol for RNA transfection into primary mononuclear phagocytes
Zhang, Y., Béland, L., Roussel, S., Bertrand, N., Hébert, S. S., & Vallières, L. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae059 · Cited by 6
Promising RNA-based therapies for viral infections, genetic disorders, and cancer
Musa, D. A., Raji, M. O., Sikiru, A. B., Aremu, H. K., & Aigboeghian, E. A. (2024) · Academia molecular biology and genomics. · doi:10.20935/acadmolbiogen7329 · Cited by 7
Intradermal delivery of SARS-CoV-2 RBD3-Fc mRNA vaccines via a needle-free injection system induces robust immune responses in rats
Wang, C., Tang, X., Jiang, C., Zhang, Y., Han, B., Sun, Y., Guo, J., Peng, H., Wang, Z., Wang, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1530736 · Cited by 5

Authors: Teo, S. P.
Affiliations: Raja Isteri Pengiran Anak Saleha Hospital (BN)
Corresponding author: Teo, Shyh Poh
ORCID: Teo, Shyh Poh
Venue: Journal of Pharmacy Practice
Publisher: SAGE Publications
Published: 2021-04-12
Volume: 35
Issue: 6
Pages: 947-951
ISSN: 0897-1900 (ISSN-L)
1531-1937
DOI: 10.1177/08971900211009650
OpenAlex: W3154719862
Cited by: 191
References: 26
Citations by year: 2026: 24 · 2025: 42 · 2024: 35 · 2023: 39 · 2022: 37 · 2021: 14
FWCI: 3.65
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Pharmacy Practice (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords: COVID-19 mRNA vaccine, BNT162b2, mRNA-1273, SARS-CoV-2, vaccine development, vaccine efficacy, immunogenicity, vaccine safety, emergency use authorization, vaccine thermostability, underrepresented groups
MeSH terms: COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Humans, RNA, Viral, United States, Viral Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks